临床内科杂志
臨床內科雜誌
림상내과잡지
Journal of Clinical Internal Medicine
2015年
9期
611-613
,共3页
胡军%杨少娟%朱琳%江燕丽%廖丹%张瑶%陈敏
鬍軍%楊少娟%硃琳%江燕麗%廖丹%張瑤%陳敏
호군%양소연%주림%강연려%료단%장요%진민
左卡尼汀%糖尿病%慢性心力衰竭%甲状腺激素
左卡尼汀%糖尿病%慢性心力衰竭%甲狀腺激素
좌잡니정%당뇨병%만성심력쇠갈%갑상선격소
L-carnitine%Diabetes%Chronic heart failure%Thyroid hormones
目的:观察左卡尼汀治疗2型糖尿病合并慢性心力衰竭(CHF)患者甲状腺功能的变化。方法选择64例糖尿病合并慢性心力衰竭患者,随机分为左卡尼汀组及对照组各32例。两组均行常规抗心力衰竭治疗,左卡尼汀组在常规治疗基础上加用左卡尼汀2 g 静脉泵入,每天2次,共14天,检测用药14天后左心室射血分数(LVEF)、左心室短径缩短率(LVFS)、心排出量(CO)、氨基末端脑钠素前体(NT-pro-BNP)、三碘甲状腺原氨酸(T3)、游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)、促甲状腺激素(TSH)等指标水平,并分别与治疗前及对照组各项指标进行比较。结果与治疗前及对照组比较,左卡尼汀组在改善心力衰竭患者心功能的同时,T3和 FT3水平上升(P <0.05),未见明显不良反应,且葡萄糖(GLU)、三酰甘油(TG)、胆固醇(CHO)较治疗前明显下降(P <0.05)。结论左卡尼汀治疗2型糖尿病合并慢性心力衰竭疗效较好,能改善患者甲状腺功能,且无明显不良反应。
目的:觀察左卡尼汀治療2型糖尿病閤併慢性心力衰竭(CHF)患者甲狀腺功能的變化。方法選擇64例糖尿病閤併慢性心力衰竭患者,隨機分為左卡尼汀組及對照組各32例。兩組均行常規抗心力衰竭治療,左卡尼汀組在常規治療基礎上加用左卡尼汀2 g 靜脈泵入,每天2次,共14天,檢測用藥14天後左心室射血分數(LVEF)、左心室短徑縮短率(LVFS)、心排齣量(CO)、氨基末耑腦鈉素前體(NT-pro-BNP)、三碘甲狀腺原氨痠(T3)、遊離三碘甲狀腺原氨痠(FT3)、血清遊離甲狀腺素(FT4)、促甲狀腺激素(TSH)等指標水平,併分彆與治療前及對照組各項指標進行比較。結果與治療前及對照組比較,左卡尼汀組在改善心力衰竭患者心功能的同時,T3和 FT3水平上升(P <0.05),未見明顯不良反應,且葡萄糖(GLU)、三酰甘油(TG)、膽固醇(CHO)較治療前明顯下降(P <0.05)。結論左卡尼汀治療2型糖尿病閤併慢性心力衰竭療效較好,能改善患者甲狀腺功能,且無明顯不良反應。
목적:관찰좌잡니정치료2형당뇨병합병만성심력쇠갈(CHF)환자갑상선공능적변화。방법선택64례당뇨병합병만성심력쇠갈환자,수궤분위좌잡니정조급대조조각32례。량조균행상규항심력쇠갈치료,좌잡니정조재상규치료기출상가용좌잡니정2 g 정맥빙입,매천2차,공14천,검측용약14천후좌심실사혈분수(LVEF)、좌심실단경축단솔(LVFS)、심배출량(CO)、안기말단뇌납소전체(NT-pro-BNP)、삼전갑상선원안산(T3)、유리삼전갑상선원안산(FT3)、혈청유리갑상선소(FT4)、촉갑상선격소(TSH)등지표수평,병분별여치료전급대조조각항지표진행비교。결과여치료전급대조조비교,좌잡니정조재개선심력쇠갈환자심공능적동시,T3화 FT3수평상승(P <0.05),미견명현불량반응,차포도당(GLU)、삼선감유(TG)、담고순(CHO)교치료전명현하강(P <0.05)。결론좌잡니정치료2형당뇨병합병만성심력쇠갈료효교호,능개선환자갑상선공능,차무명현불량반응。
Objective To observe the changes of thyroid function in L-carnitine treatment of type 2 diabetes mellitus(DM)with chronic heart failure(CHF)patients.Methods 64 cases DMpatients with CHF were randomly divided into L-carnitine group(32 cases)and control group(32 cases).Both groups underwent conventional anti-heart failure treatments.Besides,the L-carnitine group were treated with 2 g of L-carnitine in intravenous pump twice a day in a total amount of 14 d.Indicators such as left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS),cardiac output(CO),N-terminal pro-brain natriuretic peptide(NT-pro-BNP),triiod-thyronine(T3 ),free triiodthyronine(FT3 ),free thyrox-ine(FT4 )and thyroid stimulating hormone(TSH)were detected 14 days after medical treatments,and each indicator was compared with the one before the treatments and the corresponding control group data re-spectively.Results L-carnitine improved heart function in patients with heart failure,T3 ,FT3 level com-pared with before treatment and the control group had significant increased difference(P <0.05),showing no obvious adverse reactions,and glucose(GLU),triglyceride(TG),cholesterol(CHO)had sharp tenden-cies of declining compared to those before treatments.Conclusion L-carnitine have a significant effect on the treatments of type 2 diabetes mellitus with chronic heart failure.It can improve thyroid function and have no significant adverse reactions.